ERIS PHARMA GmbH BALANCE SHEET AS AT MARCH 31, 2021

			Amount in EUR 31-Mar-21
Α	ASSETS		
- 1	Non-current assets		
	(a) Other intangible assets		2,148
	(b) Intangibles assets under development		57,706
	Total non-current assets		59,855
ı	Current assets		
	(a) Inventories		115,597
	(b) Financial assets		
	(i) Trade receivables	1	88,793
	(il) Cash and cash equivalents	2	743
	(c) Other current assets	3	(4,674)
	Total current assets		200,459
	TOTAL ASSETS		260,314
В	EQUITY AND LIABILITIES		
ı	Equity		
	(a) Equity share capital	4	25,000
	(b) Other equity	5	(257,700)
	Total Equity		(232,700)
П	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings		287,570
	(Ii) Trade payables	6	55,635
	(iil) Other financial liabilities	7	7,864
	(b) Provisions	8	141,945
	Total current liabilities		493,014
	TOTAL EQUITY AND LIABILITIES		260,314

ERIS PHARMA GmbH STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2021

			Amount in EUR
	Particulars	Note No.	31-Mar-21
1	Revenue from operations	9	180,505
2	Other Income		829
3	Total Revenue (1+2)	_	181,334
4	Expenses		
	(a) Cost of Goods sold	10	87,712
	(b) Finance costs	11	15,783
	(c) Depreciation and amortisation expense		12,169
	(d) Other expenses	12	71,371
	Total expenses	_	187,035
5	Profit / (Loss) before exceptional items and taxes (3-4)		(5,701)
6	Exceptional Item		-
7	Profit / (Loss) before taxes (5+6)		(5,701)
8	Tax Expense:		
	(1) Current tax		-
	(2) Deferred tax		-
	Total tax expenses		
9	Profit / (Loss) for the year after tax		(5.701)

ERIS PHARMA GmbH

Notes forming part of financial statement

Note

No.

1 Trade receivables Amount in E

	/ z z
Particulars	31-Mar-21
Unsecured	
Considered good	88,793
Considered doubtful	
	88,793
Less: Allowance for doubtful trade receivables	
Total	88,793

2 Cash and cash equivalents

Amount in EUR

Particulars	31-Mar-21
Cash in hand	-
Balances with banks:	
In current accounts	743
Total	743

3 Other current assets

Amount in EUR

Particulars	31-Mar-21
Unsecured, considered good	
Balances with government authorities:	
- Vat refund receivable	(5,131)
Prepaid Expenses	457
Total	(4,674)

4 Share capital Amount in EUR

•	Share capital	
	Particulars	31-Mar-21
	Issued, subscribed and fully paid-up	
	Equity share capital	25,000
	Total	25,000

5 Reserves and surplus

Amount in EUR

Particulars	31-Mar-21
Surplus in statement of profit and loss	
Opening balance	(251,999)
Add: Profit / (Loss) for the year	(5,701)
Closing balance	(257,700)
Total	(257,700)

6 Trade payables

Amount in EUR

Particulars	31-Mar-21
Trade payable	55,635
Total	55,635

7 Other Current financial Liabilities

Amount in EUR

Particulars	31-Mar-21
Payable to group entities	-
Other payables:	
- Statutory remittances	7,864
Total	7,864

8 Provisions

Amount in EUR

Particulars	31-Mar-21
Provision for expenses	141,945
Total	141,945

ERIS PHARMA GmbH

Notes forming part of financial statement

Note

No.

9 Revenue from operations

Amount in EUR

Particulars	31-Mar-21
Sale of Product	180,505
Total	180,505

10 Cost of goods sold

Amount in EUR

Particulars	31-Mar-21
Opening stock	18,768
Add: Purchases	184,541
Closing stock	115,597
Total	87,712

11 Finance cost

Amount in EUR

Particulars	31-Mar-21
Finance Charges	15,783
Total	15,783

12 Other expenses

Amount in EUR

Particulars	31-Mar-21
Consumables	1,325
Freight and forwarding	37,950
Rent	4,485
Rates & taxes	5,518
Repairs & Maintenance	416
Insurance	6,767
Communication expenses	520
Legal expenses	1,034
Professional fees	10,744
Payment to Auditors - For Statutory Audit	1,460
Miscellaneous Expense	1,151
Total	71,371